Hydralazine Linked to Slight Increase in Vasculitis Risk, But Overall Incidence Remains Low: Study Finds
Canada: A recent study published in JAMA Network Open suggests that while hydralazine use may be linked to a slightly higher risk of vasculitis compared with other commonly used antihypertensive drugs, the overall risk remains very low and is unlikely to be clinically significant. The research was conducted by Deena Fremont, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, and colleagues.
Hydralazine is a selective cardiovascular medication that has been associated in earlier reports with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, a rare but potentially serious inflammatory condition affecting blood vessels. However, large-scale population-based data evaluating this risk have been limited until now.
To address this gap, researchers conducted a retrospective cohort study involving older adults in Ontario, Canada. The study included 583,136 individuals aged 66 years and above who were newly prescribed antihypertensive medications between 2008 and 2021. Among them, 40,748 patients received hydralazine, while 542,388 were prescribed angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), which served as the comparator group.
The primary outcome assessed was the occurrence of vasculitis, identified using standardized diagnostic codes.
The researchers reported the following findings:
- Vasculitis events were rare in both treatment groups during the follow-up period.
- A slightly higher incidence of vasculitis was observed in patients receiving hydralazine compared to those on ACE inhibitors or ARBs.
- Vasculitis occurred in 0.8% of hydralazine users versus 0.5% in the comparator group.
- The absolute risk difference between the groups was small (0.3 percentage points).
- Statistical analysis suggested a modestly increased risk associated with hydralazine use.
- The association was no longer statistically significant after accounting for competing risks such as death.
- Overall, the rarity of vasculitis indicates that the increased risk is unlikely to be clinically meaningful for most patients.
The authors emphasize that these results should be interpreted cautiously. The study relied on hospital-based diagnostic coding, which may have missed milder cases managed in outpatient settings. Additionally, the use of broad diagnostic criteria could have led to overestimation of vasculitis cases. The study population was limited to older adults, which may affect the generalizability of the findings to younger patients. Other limitations included potential misclassification, unmeasured confounding factors, and the inability to capture hydralazine use exclusively during hospital stays.
Interestingly, similar risk patterns were observed when alternative comparator drugs, such as alpha-blockers, were analyzed, suggesting that residual confounding cannot be entirely excluded.
Overall, the study provides reassurance that although hydralazine may be associated with a small increase in vasculitis risk, such events are rare and unlikely to influence clinical decision-making in most cases. The authors conclude that concerns about vasculitis should not be the primary factor guiding the use of hydralazine, particularly when its benefits in managing certain cardiovascular conditions are considered.
Reference:
Fremont D, Dhaliwal S, Canney M, et al. Hydralazine Use and Risk of Vasculitis. JAMA Netw Open. 2026;9(3):e261943. doi:10.1001/jamanetworkopen.2026.1943
Next Story